Conduit Pharmaceuticals IncNASDAQ:CDT
- LAST PRICE3.1700
- TODAY'S CHANGE (%)0.0700 (2.2581%)
- Bid / Lots2.4500/ 5
- Ask / Lots3.2000/ 4
- Open / Previous Close3.0500 / 3.1000
- Day Range
- 52 Week Range
- Volume5,588
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CDT |
|---|---|---|
| 03:14 ET | 100 | 3.05 |
| 03:30 ET | 200 | 3.1 |
| 03:32 ET | 200 | 3.0737 |
| 03:50 ET | 470 | 3.09 |
| 03:54 ET | 100 | 3.1 |
| 03:57 ET | 434 | 3.1 |
| 03:59 ET | 700 | 3.17 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Conduit Pharmaceuticals Inc | 234.0M | -1,025.9x | --- |
Aldeyra Therapeutics Inc | 231.5M | -6.2x | --- |
Verastem Inc | 237.4M | -2.3x | --- |
XBiotech Inc | 239.6M | -9.8x | --- |
Quantum-Si Inc | 233.9M | -2.4x | --- |
Prelude Therapeutics Inc | 223.5M | -2.0x | --- |
Company Information
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis (HT and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
Contact Information
- Headquarters
- 4995 Murphy Canyon Road, Suite 300SAN DIEGO, CA, United States 92123
- Phone
- 760-471-8536
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Freda Lewis-Hall
- Chief Executive Officer, Director
- David Tapolczay
- Chief Financial Officer
- Adam Sragovicz
- Director
- James Bligh
- Director
- Andrew Regan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $234.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 73.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.00 |
Book Value | $7.66 |
P/E Ratio | -1,025.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | 1,946.0x |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
